Prevalence of the metabolic syndrome in schizophrenic patients receiving second-generation antipsychotic agents--a cross-sectional study.
Prevalence of the metabolic syndrome in schizophrenic patients receiving second-generation antipsychotic agents--a cross-sectional study.
复制标题
DOI：
10.1177/0897190012442220
复制
发表时间：
2012-06-01
影响因子：
1.3
通讯作者：
Malleshappa, Anil
中科院分区：
文献类型：
--
作者：
Kagal, Urmila A;Torgal, Shashikant S;Malleshappa, Anil
目的：本研究旨在评估接受第二代抗精神病药物的精神分裂症患者代谢综合征的患病率，并确定用于筛查这些患者代谢综合征的最敏感和最特异的临床参数。 材料和方法：本研究在一家三级甲等医院进行。 80 名被诊断患有精神分裂症并接受单一第二代抗精神病药物治疗 3 个月或更长时间的患者在获得书面知情同意后被纳入该研究。使用美国心脏协会和国家心肺血液研究所 (AHA NHLBI) 修订的国家胆固醇教育计划成人治疗小组 III (NCEP ATP III) 标准对患者进行代谢综合征筛查。结果：发现代谢综合征的患病率为 35%。代谢综合征筛查敏感性最高的临床参数是低血清高密度脂蛋白胆固醇，敏感性为89.28%。空腹血糖升高和腰围增加具有最高且同等的特异性，均为90.38%。结论：接受第二代抗精神病药物的精神分裂症患者代谢综合征的患病率较高。提高精神科医生对这一事实的认识将有助于预防、发现和治疗这种与相当大的发病率和死亡率相关的疾病。
OBJECTIVE: The present study was taken up to assess the prevalence of the metabolic syndrome in schizophrenic patients receiving second-generation antipsychotic agents and to determine the most sensitive and specific clinical parameters used for screening of metabolic syndrome in these patients.MATERIALS AND METHODS: The present study was taken up in a tertiary care hospital. Eighty patients diagnosed with schizophrenia and receiving a single second-generation antipsychotic for 3 months or more were enrolled in the study after obtaining written informed consent. Patients were screened for metabolic syndrome using American Heart Association and National, Heart, Lung and Blood Institute (AHA NHLBI)-modified National Cholesterol Education Program, Adult Treatment Panel III (NCEP ATP III) criteria.RESULTS: Prevalence of metabolic syndrome was found to be 35%. The clinical parameter with highest sensitivity for screening of metabolic syndrome is low-serum high-density lipoprotein cholesterol with a sensitivity of 89.28%. Elevated fasting blood glucose and increased waist circumference were found to have highest and equal specificity of 90.38%.CONCLUSION: There is a high prevalence of the metabolic syndrome in patients with schizophrenic patients receiving second-generation antipsychotic agents. Increasing awareness of this fact among psychiatrists will help to prevent, detect, and treat this condition that is associated with considerable morbidity and mortality.